CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma

A Study of CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma

Trial Details

NCT ID
NCT04661020
Phase
PHASE2
Sponsor
Zhejiang University
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • CD19 CAR-T cells
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Age no less than 18, no gender limit;
  • Newly diagnosed high-risk Large B-cell Lymphoma, which was defined by the following criteria: (1) DLBCL not otherwise specified with an IPI score ≥…
  • Confirmed CD19 and CD20 postive expressions in lymphoma cells
  • ECOG score 0-2;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →